R

Resmed

Cloud-connected medical devices and software platforms

Associate Manager - Supply Chain Finance Centre of Excellence, Centre of Excellence

Full-TimeUpdated on 10/15/2026
No salary listed
Senior, Expert
Bachelor's
Kuala Lumpur, Federal Territory of Kuala Lumpur, Malaysia
In Person
AccountingFinancial Accounting, Cost & Management Accounting

About the job

Requirements
  • A bachelor's degree in Accounting, Finance, or a related discipline.
  • Seven to ten years of relevant experience in Operations Accounting, Cost Accounting, Manufacturing Finance, or Financial Reporting within a multinational environment.
  • Prior manufacturing experience and a strong understanding of inventory accounting, standard costing, and month-end close processes.
  • Previous experience leading or mentoring a finance team, with the ability to develop people and foster a collaborative team environment.
  • Experience working within a Shared Services Centre or Centre of Excellence environment.
  • Strong knowledge of manufacturing accounting principles, inventory valuation, standard costing, and financial reporting.
  • Hands-on experience performing month-end close activities, including journal entries, reconciliations, and financial analysis.
  • Experience with ERP systems such as SAP, Oracle, or equivalent; knowledge of manufacturing modules is an advantage.
  • Strong analytical and problem-solving skills with attention to detail.
  • Advanced Microsoft Excel skills; experience with Power BI, automation tools, or process improvement technologies is advantageous.
  • Ability to lead by example while balancing people leadership with hands-on operational execution.
  • Proven experience driving process improvements, standardization, or finance transformation initiatives.
  • Strong stakeholder management skills to collaborate across Finance, Operations, and Shared Services teams.
  • Ability to identify opportunities to simplify, standardize, and improve finance processes.
  • Ability to manage competing priorities and meet reporting deadlines in a fast-paced, evolving environment.
  • Ability to work effectively across multiple countries and cultures.
  • Ability to balance operational delivery with continuous improvement, remaining hands-on during critical reporting periods while driving longer-term transformation initiatives.
Responsibilities
  • Take ownership of month-end and quarter-end close activities for assigned manufacturing and distribution entities, ensuring timely and accurate financial reporting.
  • Perform and review journal entries, balance sheet reconciliations, inventory accounting, manufacturing variance analysis, and standard costing activities.
  • Support management costing, cost roll-ups, product costing, and inventory valuation processes.
  • Partner with site Finance Business Partners to resolve operational accounting issues and support business decisions.
  • Provide hands-on operational support during peak close periods and assist the team in meeting reporting deadlines.
  • Ensure compliance with accounting policies, SOX requirements, and internal controls.
  • Lead and develop a growing Operations Accounting team based in Kuala Lumpur.
  • Coach, mentor, and develop team members while fostering a collaborative, high-performing culture.
  • Establish clear roles, responsibilities, and service delivery standards within the COE.
  • Balance workload across the team to optimize capacity and ensure continuity during month-end close.
  • Review Operations Accounting activities across manufacturing entities to identify opportunities for consolidation, standardization, and simplification.
  • Drive continuous improvement initiatives through process redesign, automation, and system enhancements.
  • Develop standard operating procedures and governance frameworks to improve consistency across sites.
  • Partner with Finance Business Partners and Operations leaders to improve end-to-end finance processes.
  • Identify opportunities to use automation, digital technologies, and AI-enabled solutions to improve finance processes, controls, and service delivery.
  • Partner with Supply Chain Finance Business Partners across manufacturing sites.
  • Build trusted relationships with Operations, Planning, Corporate Accounting, and Shared Services teams.
  • Support finance transformation initiatives and implementation of the Supply Chain Finance COE operating model.
Desired Qualifications
  • CPA, CA, or equivalent professional qualification.
  • Experience with manufacturing modules in ERP systems.
  • Experience with Power BI, automation tools, or process improvement technologies.

About the company

ResMed creates cloud-connected medical devices and software platforms to treat and manage sleep apnea, COPD, and other chronic diseases. Its devices (like sleep therapy gear) collect patient data and deliver therapy, while connected software platforms enable remote monitoring, coaching, and caregiver support. The company sells medical devices and offers software subscriptions, generating revenue from product sales and ongoing service fees. Unlike some competitors, ResMed combines hardware with cloud-based analytics and a broad ecosystem that supports patients, healthcare professionals, and caregivers across more than 120 countries. Its goal is to improve patient care and quality of life while reducing hospital visits and overall healthcare costs.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1989

Get referred to Resmed

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2026 guidance shows 5%-7% revenue growth and 12%-14% core EPS growth.
  • MatrixCare closed September 1, 2026, freeing capital for higher-margin core businesses.
  • ResMed's connected network and Oura partnership expand diagnosis and PAP adoption funnels.

What critics are saying

  • Astral no-new-sales in fiscal 2027 removes $75 million revenue and damages trust.
  • KPMG exit and PwC onboarding increase reporting disruption risk before the next 10-Q.
  • Philips Respironics' U.S. return in 2027 can compress pricing and share quickly.

What makes Resmed unique

  • ResMed's cloud-connected AirSense platform locks in recurring resupply and adherence data.
  • Noctrix acquisition broadens ResMed beyond apnea into restless legs syndrome treatments.
  • MatrixCare sale and core-device focus sharpen execution around sleep, breathing, and home care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Holidays

Parental Leave

401(k) Retirement Plan

Employee Assistance Program (EAP)

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

7%

2 year growth

7%
Yahoo Finance
Sep 19th, 2026
ResMed achieves 9% revenue growth to $1.5B amid sleep apnea demand, but fiscal 2027 guidance misses expectations

ResMed Inc. (NYSE: RMD) is positioned to benefit from growing awareness and penetration in the global obstructive sleep apnea treatment market, backed by its robust product portfolio. The portfolio includes CPAP and APAP machines, led by the AirSense platform, along with masks and accessories. In the fourth quarter of fiscal 2026, ResMed's revenue increased 9% year over year to $1.5 billion. Americas device revenue rose 6%, whilst total Americas Sleep and Breathing Health revenue increased 8%. On 15 September, RBC Capital upgraded ResMed to Outperform, raising its price target to $262 from $244. However, the company faces competitive pressures, particularly from the potential return of Philips Respironics to the US market. ResMed issued 2027 revenue guidance of $5.75 billion to $5.85 billion, below analysts' expectations of $5.92 billion.

Yahoo Finance
Sep 14th, 2026
ResMed falls 20.5% over 52 weeks despite Q4 revenue beat amid margin compression

ResMed, a San Diego-based developer of medical devices for respiratory disorders, has underperformed the healthcare sector over the past year. The company, valued at $31.5 billion, has declined 20.5% over 52 weeks, whilst the State Street Healthcare Select Sector SPDR ETF rose 21% during the same period. The stock fell 5.1% on 7 August following its Q4 earnings release. Whilst revenue increased 8.6% year-over-year and adjusted earnings per share of $2.95 beat forecasts, operating margin compressed to 30.7% from 33.7% the previous year. Management attributed the margin decline to higher R&D and supply chain costs amid inflation. Despite recent underperformance, the stock has gained 13.5% over the past three months. Wall Street analysts maintain a "moderate buy" rating, with a mean price target suggesting 9.1% upside potential.

Heartstrong Sleep
Sep 6th, 2026
Heartstrong Sleep daily - sep 6, 2026.

Heartstrong Sleep daily - sep 6, 2026. About Heartstrong | September 6, 2026 Segment 1 - intro / lead story. Good morning. It's Sunday, September 6th, and there's a genuine milestone worth covering in sleep medicine this weekend. For the first time, the FDA is formally reviewing a prescription pill designed to treat obstructive sleep apnea. The drug is called AD109, developed by a small biotech company called Apnimed. The FDA accepted their New Drug Application in July, meaning it's now under active review. If AD109 clears - and a decision could come as early as the first quarter of 2027 - it would be the first oral medication ever approved specifically for OSA. Let's put that in perspective. Sleep apnea has been treated almost exclusively with mechanical solutions since CPAP therapy was introduced in the early 1980s. Oral appliances and surgery exist as alternatives, but a once-nightly pill that directly targets the airway muscle dynamics that cause apnea events is a genuinely new category. Segment 2 - AD109 what it means. In Phase 3 clinical trials, AD109 cut apnea events per hour by about 44 percent. That's meaningful, but it's worth comparing to CPAP. When patients use CPAP consistently, most see a 90 percent or greater reduction in apnea events. So AD109 is not positioned to replace CPAP for most patients - and it shouldn't be. It's aimed at the large group of people who cannot tolerate CPAP or won't stick with it long-term. That group is enormous. Research consistently shows that somewhere between 70 and 80 percent of people with clinically significant sleep apnea in the U.S. are either undiagnosed or untreated. A pill that can bring even a fraction of those people into treatment - and then connect them with a testing and resupply pathway - represents a real shift in the pipeline. For programs like Heartstrong Sleep, the downstream implication is that more patients may be entering care through a new front door. Whether they eventually transition to or add CPAP therapy depends on severity and tolerance, but diagnosis and engagement is the starting point for everything else. Segment 3 - resmed ers Congress data. Now to Barcelona. ResMed is presenting research this week at the European Respiratory Society Congress, which runs September 5th through the 9th. One finding from their dataset is worth highlighting. The data shows that each additional hour of nightly PAP therapy use is associated with a statistically measurable reduction in mortality risk among people with obstructive sleep apnea. This builds on a body of prior research, but what ResMed is adding is real-world usage data from their connected device network - which covers tens of millions of active patients globally. That scale matters. It's not a controlled trial with a small cohort; it's observational data from an enormous, real-world population. The direction of the finding is consistent: more nightly use, better outcomes. And the dose-response relationship - where each additional hour contributes to the benefit - gives clinicians a concrete message for patients who are using their device for 3 hours a night and wondering if it's worth the effort. The answer from this data is yes, and more is better. For resupply and adherence teams, this data is a clinical anchor. When a patient calls because their mask is uncomfortable or they're thinking about stopping therapy, the conversation isn't just about compliance metrics or insurance coverage windows. It's about survival benefit - framed in plain language. Segment 4 - market outlook. Stepping back to the broader market picture. MarketsandMarkets estimates the U.S. sleep apnea devices market at approximately 3.1 billion dollars in 2026, with a forecast of 4.5 billion by 2031. That's roughly 8 percent compound annual growth over five years, driven by rising diagnosis rates, expanded home sleep testing, and growing employer and insurer focus on sleep health as a preventive care priority. For a resupply-focused business like Heartstrong Sleep, that trajectory points to a steadily growing patient population over the next several years. The competitive question is which providers build the strongest patient relationships at diagnosis - and sustain them through the full therapy journey.

INSURASALES
Aug 31st, 2026
INSURASALES

Discover how Manufacturers Life Insurance's investment in ResMed signals trends in healthcare investments crucial for insurance professionals.

GlobeNewswire
Aug 27th, 2026
Resmed announces participation in the 24th Annual Morgan Stanley Global Healthcare Conference.

Resmed announces participation in the 24th Annual Morgan Stanley Global Healthcare Conference. August 27, 2026 16:05 ET | Source: Resmed, Inc. SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) - Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 24th Annual Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026. Resmed's webcast presentation will begin at approximately 10:00 a.m. (Eastern Time). More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The audio-only webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible for the following ninety (90) days. About Resmed Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We're relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we're redefining sleep health at Resmed.com and follow @Resmed. | For investors | For media | | +1 858.221.3304 | +1 619.510.1281 | | [email protected] | [email protected] |